Aristides Capital’s Myriad Genetics MYGN Stock Holding History

Aristides Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,500	Closed	-$199K	–	294
2024 Q4	$199K	Buy	+14,500	New	+$268K	0.04%	244

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aristides Capital's MYGN Position: Q1 2025 in Review

Aristides Capital sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 14,500 shares — an estimated $199K sold.

Aristides Capital first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $199K in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Aristides Capital reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 14,500 Myriad Genetics shares in Q1 2025, an estimated $199K.
Aristides Capital first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
Aristides Capital's Myriad Genetics position peaked at $199K in Q4 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.